Innovation & Research

Oncology

Developing effective cancer treatments remains one of the biggest priorities in healthcare today, and we are committed to making a difference to the lives of patients with difficult-to-treat cancers.

Constant advancement in our understanding of the molecular mechanisms underpinning the emergence, growth and spreading of tumors is expanding the potential for targeted approaches to treat cancer. This progress is based on evidence that the molecular and genetic profiles of tumors are as different as the patients in whom they occur, and better outcomes can be achieved by treating patients based on the specific characteristics of a tumor.

Menarini’s ability to identify and develop cancer treatments that specifically target distinctive molecular or genetic profiles of tumors can provide greater efficacy, improved safety, and hence better outcomes for patients. At the same time, dissecting a tumor’s genetic heterogeneity is essential to understanding tumor clonal evolution, providing an opportunity to develop new precision medicine strategies to address the emergence of resistance to current treatments.

That is why our work in oncology is focused both on therapeutics and diagnostics. We invest in the development of precision medicine through our pipeline of investigational drugs, while developing innovative technologies for the detection and analysis of circulating tumor cells, that enable their molecular characterization.

Through a precision medicine approach, we work with patients that carry specific molecular markers contributing to tumor growth and the spreading of tumor cells. These patients are expected to receive the most tangible benefit from treatment by achieving improved therapeutic results with less side effects.

As part of our strong commitment to oncology, in June 2020 Menarini acquired Stemline Therapeutics, a New-York based commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, strengthening Menarini’s oncology pipeline with the addition of both commercial and clinical-stage assets.

Our pipeline and products

Our pipeline and products

Find out more about our pipeline of potential new treatments

Read More
Our technolohies for rare cells ananlysis

Our technologies for rare cells analysis

Find out more about our technologies and the work of Menarini Silicon Biosystems

Read More
foto_team

Our partners in oncology

Partnerships are an integral part of our R&D strategy. By leveraging our expertise and resources, we work with our partners to transform their discoveries into innovative health care solutions that can make the difference for cancer patients.

First slide

OBT Management Team

“We are delighted to collaborate with Menarini, a company that has made impressive achievements in biologics development and demonstrated an enduring commitment to the development of innovative cancer therapies. This creative alliance is transformational for us as it allows OBT to participate in the clinical development and future commercialization of our programs while at the same time it bolsters Menarini’s pipeline with a portfolio of the next generation of cancer drugs”

Second slide

Tatsuro Kosaka, Chugai’s Representative Director, Chairman and Chief Operating Officer.

“We are pleased to sign a license agreement for PA799 with Menarini Group. PI3K is assumed to be one of the important kinases in the signaling pathway for the proliferation, the differentiation and the survival of tumor cells. We hope that the development of PA799 by Menarini Group will bring benefit to the patients as early as possible.”

Third slide

Pawel Przewiezlikowski, Chief Executive Officer at Ryvu Therapeutics

“We are excited to sign a license agreement for SEL24 with the Menarini Group. This collaboration takes us another step closer to delivering a much-needed new treatment for AML patients. Menarini Group dedication to providing transformative therapies for people courageously facing various life-threatening diseases such as cancer, assures us that the potential of SEL24 in treatment of cancer patients will be fully realized.”

Fourth slide

Helsinn Group Team

“The strength of Helsinn’s partnership with Menarini lies in the shared commitment to progress innovative treatments for patients with unmet needs, always underpinned by the values of quality, integrity and respect.”

Previous Next



BUILDING EXCELLENCE TOGETHER

Learn more about our approach to partnerships.

Read More







Expanded access programs

 

The Menarini Group is committed to developing new therapies to address the unmet medical needs of patients suffering from rare and seriously debilitating diseases. 
We recognize that some patients who wish to access our medicines will not be eligible for clinical trials and may have no other viable treatment options available to them.
In these situations, we will consider providing pre-approval access to our investigational medicines, outside of the clinical trial setting, when certain conditions are met. 

 

More information

oncology

dermatology

Our projects in onco-hematology

The HARMONY Alliance is a European Network of excellence that captures, integrates, analyzes and harmonizes Big Data from high-quality multidisciplinary sources for the purpose of acquiring valuable knowledge across the spectrum of blood cancers i.e. hematologic malignancies (HMs).

Read More

linkedin

Careers in Oncology

Join our team to contribute to building and shaping Menarini Stemline’s Oncology business.

READ MORE

Search Menarini in the world

v

Etiam commodo dui eget wisi. Donec iaculis gravida nulla. Donec quis nibh at felis congue commodo. Etiam bibendum elit eget erat.

Partnering

Drug development is a challenging process, and success relies on the integration of innovative scientific discoveries with the necessary capabilities and resources to transform them into effective healthcare solutions.

Read More